Source: Annual Congress 2003 - Issues surrounding drug delivery
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Holz, M. Einhaus, I. Zühlke, D. Branscheid, M. Nakashima, L. Welker, F. Kanniess, K. Richter, S. Hader, L. Harrison, R. A. Jörres, H. Magnussen (Grosshansdorf, Neuss, Germany; St Paul, United States Of America). Determination of tissue concentrations of metabolites in surgical preparations following inhalation of beclomethasone-dipropionate using conventional and extrafine aerosols. Eur Respir J 2003; 22: Suppl. 45, 2980

Member's Comments

No comment yet.

Related content which might interest you: Aerosol performance of two ambroxol inhalation products upon nebulisation by the eFlow rapid Source: Eur Respir J 2006; 28: Suppl. 50, 212s Year: 2006 A novel tool for the assessment of pulmonary disposition of dry powder aerosols; the isolated and perfused rat lung exposed to budesonide, formoterol and terbutaline Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007 Plasma concentrations of four corticosteroids following inhalation Source: Eur Respir J 2005; 26: Suppl. 49, 215s Year: 2005 Urinary pharmacokinetic method to identify the relative bioavailability of beclometasone dipropionate (BDP) to the lung and body following inhalation Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 Effect of device and formulation on delivery of budesonide suspensions by nebulizers Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002 Greater esterification and retention of budesonide in the airways and lung as compared to ciclesonide after repeated intratracheal administration in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004 Hydrofluoroalkane beclomethasone dipropionate extra fine aerosol efficacy response at reduced dose compared to other inhaled corticosteroid treatment regimens Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001 Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Concentrations of ciclesonide and its metabolites in the human lung after inhalation of 1280 μg ciclesonide Source: Eur Respir J 2006; 28: Suppl. 50, 212s Year: 2006 Estimation of efficiency of new combined preparation built-in-liposomes budesonide compared with water budesonide suspension Source: Eur Respir J 2004; 24: Suppl. 48, 83s Year: 2004 The small airway inflammation of asthmatic patients who have used dry powder type inhaled steroid for moderate-long term evaluated by induced sputum and the efficacy of HFA-BDP (QVAR) inhalation Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005 Ex-vivo emitted dose characteristics for combination formulations in dry powder inhalers (DPI) Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003 Comparison of the release characteristics of formoterol dihydrate powder for inhalation delivered through two different types of multidose dry powder inhalers (MDPI) Source: Eur Respir J 2005; 26: Suppl. 49, 126s Year: 2005 Efficient deposition and absorption of orally inhaled indacaterol in the lungs Source: Annual Congress 2011 - COPD management Year: 2011 Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007 Slow particle dissolution may limit lung absorption of inhaled pharmaceuticals in the lungs Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006 Efficient deposition and sustained lung concentrations of NVA237 after inhalation via the Breezhaler® device in man Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Side effects of inhaled budesonide through different types of inhalers Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019 Different inhalation volumes do not impact on the aerodynamics of aclidinium bromide delivered using the Genuair® inhaler Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010